Bioreactor Sciences
Private Company
Funding information not available
Overview
Founded in 2018 and headquartered in Cambridge, Massachusetts, BioReactor Sciences is a private, revenue-generating company operating in the bioprocess equipment and services sector. It offers a portfolio of bench-scale bioreactors (e.g., MA-100, MA-150) and holds key patents for automated sampling and adherent culture systems. BRS employs a collaborative business model, partnering with biotechs, academic institutions, and national labs to develop integrated manufacturing solutions, positioning itself as a cost-effective alternative to larger, established bioreactor vendors.
Technology Platform
Proprietary bioreactor systems (e.g., MA-100, MA-150) with patented features for automated sampling, glucose monitoring, and adherent cell culture in multi-tray/plate formats. Focus on value-priced, easy-to-use, and scalable benchtop systems for biologics and cell therapy manufacturing.
Opportunities
Risk Factors
Competitive Landscape
BRS competes in the crowded bioprocess equipment market dominated by giants like Thermo Fisher Scientific (Cytiva), Sartorius, and Merck Millipore. Its differentiation is a focused value proposition on cost-effectiveness and hands-on service for SMEs, contrasting with the high-cost, enterprise-sales approach of larger players. Other competitors include smaller specialized firms like Eppendorf (BioFlo) and Applikon Biotechnology.